What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Ixekizumab demonstrated a clear clinical advantage over placebo in multiple trials, with statistically significant improvements in primary and secondary outcomes such as the ASAS 40 response and BASDAI scores. However, the lack of direct evidence comparing ixekizumab with TNF-alpha inhibitors limits the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
The ICERs for ixekizumab compared to conventional therapy fall within NICE’s acceptable range (£18,775 to £24,772 per QALY), indicating a strong cost-effectiveness profile. The committee concluded that ixekizumab is cost-effective when TNF-alpha inhibitors are not suitable.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates moderate improvements in HRQoL metrics, particularly through the BASDAI and BASFI scores, which reflect the treatment’s impact on daily functioning and well-being. However, the data primarily stem from clinical trials without extensive real-world validation.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ixekizumab has a very good safety profile, with mostly mild to moderate adverse events reported in clinical trials. Serious adverse events were rare, indicating a favorable tolerability compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator was conventional therapy, which is appropriate given the treatment context. However, the lack of robust direct comparisons with TNF-alpha inhibitors and reliance on indirect evidence limits the strength of the comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative patient population with axial spondyloarthritis, and the committee noted that the patient characteristics were well balanced across trial arms. However, there are some concerns regarding the generalizability of results across different subtypes.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ixekizumab can be integrated into existing care pathways with minor adjustments, primarily concerning monitoring and assessment protocols. The treatment does not require significant changes to infrastructure.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact is manageable, with the treatment being cost-effective compared to conventional therapy. The commercial arrangement also provides a discount, further supporting its economic viability.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is strong, supported by multiple randomized controlled trials. However, the reliance on indirect comparisons and some methodological concerns in the network meta-analysis introduce some uncertainty.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the generalizability of treatment effects across different patient populations and the assumptions made in the economic model. These uncertainties could impact decision-making.
